On August 30, 2026, BioMarin Pharmaceutical (BMRN) announced a comprehensive worldwide patent agreement with Ascendis Pharma, closing an extensive legal dispute centered on the C-type natriuretic peptide (CNP) technology used in Ascendis's therapeutic product Yuviwel. At the time of the announcement, BMRN stock declined 0.96%.

The two pharmaceutical companies had been locked in contentious litigation across numerous global jurisdictions, including a significant case before the U.S. International Trade Commission. The settlement resolves all outstanding matters through a single unified agreement. The stakes in such disputes are high: an adverse ITC ruling under Section 337 can result in an exclusion order barring a product from the U.S. market entirely, making settlement a common outcome in multi-jurisdiction pharmaceutical patent fights.

Under the settlement terms, Ascendis will pay BioMarin royalties of 20% on Yuviwel's net revenues generated in the United States, applied retroactively from the product's initial commercial launch date. For the European Union, Brazil, and South Korea, the royalty rate is set at 18% of net sales. These payment obligations run through May 2030.

The licensing arrangement covers Yuviwel across all existing and prospective therapeutic applications, including achondroplasia, hypochondroplasia, and potential combination treatment approaches. This framework extends BioMarin's intellectual property protection well beyond the drug's primary indication.

Terms of the Settlement Agreement

As part of the deal, BioMarin committed to withdrawing its Section 337 complaint filed with the ITC. Ongoing legal proceedings in Brazil, Denmark, Germany, South Korea, and the U.S. District Court for the Northern District of California will also be dismissed.

Ascendis further agreed not to challenge BioMarin's patent rights and consented to a bilateral regulatory non-interference provision — a notable strategic concession from Ascendis's perspective, as such clauses typically bar each party from opposing the other's regulatory filings.

The agreement reinforces the value of BioMarin's CNP technology platform, which underpins its proprietary medication VOXZOGO (vosoritide), approved for treating children diagnosed with achondroplasia. VOXZOGO, which received U.S. FDA approval in 2021, has become BioMarin's growth engine, and the royalty stream provides BioMarin a share of a competing product built on the same scientific class. BioMarin invested considerable resources over many years in developing the platform, and the royalty arrangement represents a tangible financial return on that research investment.

BioMarin's Position in Rare Disease Treatment

Alexander Hardy, BioMarin's CEO, characterized the settlement as evidence that sustained investment in rare disease therapeutic innovation yields meaningful results. The company currently markets nine commercial products and has pioneered six first-in-disease treatment options.

Analyst consensus currently rates BMRN as a Buy with an $88.00 price target, and the company maintains a market capitalization of approximately $12.52 billion.

From a technical perspective, the stock's sentiment indicator registers as a Buy, with prices positioned above key moving averages and positive MACD indicators. However, analysts have noted recent declines in profitability metrics and return on equity, alongside an elevated P/E ratio valuation.

During its latest earnings presentation, BioMarin raised its 2026 revenue projections, providing momentum as the company heads into the second half of the year.

The settlement establishes an additional royalty-based revenue stream tied to Yuviwel sales across four significant international markets, contributing to BioMarin's financial results through the May 2030 expiration date. Investors watching the company's trajectory can follow subsequent quarterly reports, which should reveal how the retroactive U.S. payments and ongoing royalties are reflected in reported results.